Upgrade to SI Premium - Free Trial

Doximity Announces Fiscal 2024 Third Quarter Financial Results

February 8, 2024 4:01 PM

Total revenues of $135.3 million, up 17% year-over-year

Net income margin of 35% and adjusted EBITDA margin of 54%

Net income growth of 43% and adjusted EBITDA growth of 32% year-over-year

SAN FRANCISCO--(BUSINESS WIRE)-- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2024 third quarter ended December 31, 2023.

"We’re proud to deliver another quarter of double-digit engagement growth across our entire platform, with a beat and raise on both our top and bottom lines,” said Jeff Tangney, co-founder and CEO of Doximity. “Our clinical workflow tools continue to drive daily use among doctors, and we now count 17 of the top 22 U.S. hospitals as enterprise software clients.”

Fiscal 2024 Third Quarter Financial Highlights

All comparisons, unless otherwise noted, are to the three months ended December 31, 2022.

Financial Outlook

Doximity is providing guidance for its fiscal fourth quarter ending March 31, 2024 as follows:

Doximity is updating guidance for its fiscal year ending March 31, 2024 as follows:

Conference Call Information

Doximity posted prepared remarks on its investor relations website at https://investors.doximity.com. Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com. The archived webcast will be available on the Company’s Investor Relations page shortly after the call.

About Doximity

Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The Company's network members include over 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better care for their patients. For more information, visit www.doximity.com.

Forward-Looking Statements

Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including (i) the timing and scope of anticipated stock repurchases; (ii) the impact of uncertainty in the current economic environment and macroeconomic uncertainty; (iii) our ability to retain existing members or add new members to our platform and maintain or grow their engagement with our platform; (iv) our ability to attract new customers or retain existing customers; (v) the impact of our prioritization of our members’ interests; (vi) breaches in our security measures or unauthorized access to members’ data; (vii) our ability to maintain or manage our growth, and other risks and factors that are beyond our control including, without limitation, those set forth in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023 and as may be updated in any subsequent Quarterly Reports on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management’s beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

DOXIMITY, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

December 31, 2023

March 31, 2023

Assets

Current assets:

Cash and cash equivalents

$

123,089

$

158,027

Marketable securities

587,149

682,972

Accounts receivable, net

97,584

107,047

Prepaid expenses and other current assets

27,191

22,289

Deferred contract costs, current

5,886

5,118

Total current assets

840,899

975,453

Property and equipment, net

11,839

11,279

Deferred income tax assets

37,204

34,907

Operating lease right-of-use assets

12,808

13,819

Intangible assets, net

28,379

31,836

Goodwill

67,940

67,940

Other assets

1,580

1,654

Total assets

$

1,000,649

$

1,136,888

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$

1,880

$

1,272

Accrued expenses and other current liabilities

34,079

31,245

Deferred revenue, current

66,694

105,238

Operating lease liabilities, current

2,109

1,752

Total current liabilities

104,762

139,507

Deferred revenue, non-current

166

198

Operating lease liabilities, non-current

12,947

13,885

Contingent earn-out consideration liability, non-current

10,787

15,942

Income taxes payable, non-current

6,532

99

Other liabilities, non-current

841

1,141

Total liabilities

136,035

170,772

Stockholders' Equity

Preferred stock

Common stock

186

194

Additional paid-in capital

808,078

762,150

Accumulated other comprehensive loss

(4,653

)

(14,083

)

Retained earnings

61,003

217,855

Total stockholders' equity

864,614

966,116

Total liabilities and stockholders’ equity

$

1,000,649

$

1,136,888

DOXIMITY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

Three Months Ended

December 31,

Nine Months Ended

December 31,

2023

2022

2023

2022

Revenue

$

135,284

$

115,262

$

357,365

$

308,086

Cost of revenue(1)

12,190

13,526

38,102

39,813

Gross profit

123,094

101,736

319,263

268,273

Operating expenses(1):

Research and development

19,946

20,519

61,835

58,645

Sales and marketing

34,956

33,220

99,612

90,375

General and administrative

9,641

9,513

27,854

26,986

Restructuring

7,936

Total operating expenses

64,543

63,252

197,237

176,006

Income from operations

58,551

38,484

122,026

92,267

Other income, net

4,481

2,461

15,223

4,173

Income before income taxes

63,032

40,945

137,249

96,440

Provision for income taxes

15,076

7,477

30,285

14,290

Net income

$

47,956

$

33,468

$

106,964

$

82,150

Net income per share attributable to Class A and Class B common stockholders:

Basic

$

0.26

$

0.17

$

0.56

$

0.43

Diluted

$

0.24

$

0.16

$

0.52

$

0.38

Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:

Basic

186,309

192,805

191,302

192,963

Diluted

200,463

212,065

207,265

213,656

(1) Costs and expenses include stock-based compensation expense as follows (in thousands):

Three Months Ended

December 31,

Nine Months Ended

December 31,

2023

2022

2023

2022

Cost of revenue

$

2,466

$

2,695

$

7,205

$

7,209

Research and development

3,080

4,002

8,874

9,416

Sales and marketing

4,060

4,856

12,752

11,912

General and administrative

2,165

2,431

6,742

6,306

Restructuring

3,646

Total stock-based compensation expense

$

11,771

$

13,984

$

39,219

$

34,843

DOXIMITY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

Three Months Ended

December 31,

Nine Months Ended

December 31,

2023

2022

2023

2022

Cash flows from operating activities

Net income

$

47,956

$

33,468

$

106,964

$

82,150

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

2,509

2,616

7,717

7,575

Deferred income taxes

9,287

9,392

Stock-based compensation, net of amounts capitalized

11,771

13,984

39,219

34,843

Non-cash lease expense

522

538

1,599

1,490

Amortization of premium (accretion of discount) on marketable securities, net

(1,683

)

471

(3,477

)

3,144

Loss on sale of marketable securities

260

593

402

1,093

Amortization of deferred contract costs

1,548

1,518

6,278

6,357

Change in fair value of contingent earn-out consideration liability

452

417

768

323

Other

788

373

457

474

Changes in operating assets and liabilities, net of effect of acquisition:

Accounts receivable

(1,135

)

3,997

8,509

6,191

Prepaid expenses and other assets

6,523

(1,727

)

(3,981

)

1,924

Deferred contract costs

(4,477

)

(4,067

)

(6,925

)

(6,409

)

Accounts payable, accrued expenses and other liabilities

10,429

7,197

2,366

2,723

Deferred revenue

(24,823

)

(19,970

)

(38,576

)

(18,098

)

Operating lease liabilities

(586

)

2

(1,168

)

(209

)

Net cash provided by operating activities

50,054

48,697

120,152

132,963

Cash flows from investing activities

Cash paid for acquisition

(53,500

)

Purchases of property and equipment

(36

)

(204

)

(147

)

(1,680

)

Internal-use software development costs

(1,288

)

(1,012

)

(4,020

)

(3,478

)

Purchases of marketable securities

(101,112

)

(39,080

)

(281,338

)

(130,257

)

Maturities of marketable securities

105,418

10,576

318,186

35,014

Sales of marketable securities

37,150

43,024

74,675

107,182

Net cash provided by (used in) investing activities

40,132

13,304

107,356

(46,719

)

Cash flows from financing activities

Proceeds from issuance of common stock upon exercise of stock options and common stock warrants

2,540

1,871

9,758

7,455

Proceeds from issuance of common stock in connection with the employee stock purchase plan

1,494

2,341

Taxes paid related to net share settlement of equity awards

(1,248

)

(1,092

)

(5,332

)

(2,353

)

Repurchase of common stock

(76,792

)

(262,976

)

(70,042

)

Payment of contingent consideration related to a business combination

(5,390

)

Net cash provided by (used in) financing activities

(75,500

)

779

(262,446

)

(62,599

)

Net increase (decrease) in cash and cash equivalents

14,686

62,780

(34,938

)

23,645

Cash and cash equivalents, beginning of period

108,403

73,674

158,027

112,809

Cash and cash equivalents, end of period

$

123,089

$

136,454

$

123,089

$

136,454

Supplemental disclosures of cash flow information

Cash paid for taxes, net of refunds

$

8,925

$

2,381

$

38,363

$

2,504

Non-GAAP Financial Measures

To supplement our consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company uses the following non-GAAP measures of financial performance:

We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.

Key Business Metrics

Reconciliation of GAAP to Non-GAAP Financial Measures

The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

Three Months Ended

December 31,

Nine Months Ended

December 31,

2023

2022

2023

2022

(unaudited)

(in thousands, except percentages)

Net income

$

47,956

$

33,468

$

106,964

$

82,150

Adjusted to exclude the following:

Acquisition and other related expenses

30

Stock-based compensation

11,771

13,984

35,573

34,843

Depreciation and amortization

2,509

2,616

7,717

7,575

Provision for income taxes

15,076

7,477

30,285

14,290

Restructuring expense

7,936

Change in fair value of contingent earn-out consideration liability

452

417

768

323

Other income, net

(4,481

)

(2,461

)

(15,223

)

(4,173

)

Adjusted EBITDA

$

73,283

$

55,501

$

174,020

$

135,038

Revenue

$

135,284

$

115,262

$

357,365

$

308,086

Net income margin

35.4

%

29.0

%

29.9

%

26.7

%

Adjusted EBITDA margin

54.2

%

48.2

%

48.7

%

43.8

%

Three Months Ended

December 31,

Nine Months Ended

December 31,

2023

2022

2023

2022

(unaudited)

(in thousands)

Net cash provided by operating activities

$

50,054

$

48,697

$

120,152

$

132,963

Purchases of property and equipment

(36

)

(204

)

(147

)

(1,680

)

Internal-use software development costs

(1,288

)

(1,012

)

(4,020

)

(3,478

)

Free cash flow

$

48,730

$

47,481

$

115,985

$

127,805

Other cash flow components:

Net cash provided by (used in) investing activities

$

40,132

$

13,304

$

107,356

$

(46,719

)

Net cash provided by (used in) financing activities

$

(75,500

)

$

779

$

(262,446

)

$

(62,599

)

Three Months Ended

December 31,

Nine Months Ended

December 31,

2023

2022

2023

2022

(unaudited)

(in thousands, except per share data and percentages)

GAAP cost of revenue

$

12,190

$

13,526

$

38,102

$

39,813

Adjusted to exclude the following:

Stock-based compensation

(2,466

)

(2,695

)

(7,205

)

(7,209

)

Amortization of acquired intangibles

(137

)

(274

)

(410

)

Non-GAAP cost of revenue

$

9,724

$

10,694

$

30,623

$

32,194

GAAP gross profit

$

123,094

$

101,736

$

319,263

$

268,273

Adjusted to exclude the following:

Stock-based compensation

2,466

2,695

7,205

7,209

Amortization of acquired intangibles

137

274

410

Non-GAAP gross profit

$

125,560

$

104,568

$

326,742

$

275,892

GAAP gross margin

91.0

%

88.3

%

89.3

%

87.1

%

Non-GAAP gross margin

92.8

%

90.7

%

91.4

%

89.6

%

GAAP research and development expense

$

19,946

$

20,519

$

61,835

$

58,645

Adjusted to exclude the following:

Stock-based compensation

(3,080

)

(4,002

)

(8,874

)

(9,416

)

Non-GAAP research and development expense

$

16,866

$

16,517

$

52,961

$

49,229

GAAP sales and marketing expense

$

34,956

$

33,220

$

99,612

$

90,375

Adjusted to exclude the following:

Stock-based compensation

(4,060

)

(4,856

)

(12,752

)

(11,912

)

Amortization of acquired intangibles

(1,061

)

(1,061

)

(3,183

)

(3,185

)

Change in fair value of contingent earn-out consideration liability

(452

)

(417

)

(768

)

(323

)

Non-GAAP sales and marketing expense

$

29,383

$

26,886

$

82,909

$

74,955

GAAP general and administrative expense

$

9,641

$

9,513

$

27,854

$

26,986

Adjusted to exclude the following:

Acquisition and other related expenses

(30

)

Stock-based compensation

(2,165

)

(2,431

)

(6,742

)

(6,306

)

Non-GAAP general and administrative expense

$

7,476

$

7,082

$

21,112

$

20,650

GAAP operating expense

$

64,543

$

63,252

$

197,237

$

176,006

Adjusted to exclude the following:

Acquisition and other related expenses

(30

)

Stock-based compensation

(9,305

)

(11,289

)

(28,368

)

(27,634

)

Amortization of acquired intangibles

(1,061

)

(1,061

)

(3,183

)

(3,185

)

Change in fair value of contingent earn-out consideration liability

(452

)

(417

)

(768

)

(323

)

Restructuring

(7,936

)

Non-GAAP operating expense

$

53,725

$

50,485

$

156,982

$

144,834

GAAP operating income

$

58,551

$

38,484

$

122,026

$

92,267

Adjusted to exclude the following:

Acquisition and other related expenses

30

Stock-based compensation

11,771

13,984

35,573

34,843

Amortization of acquired intangibles

1,061

1,198

3,457

3,595

Change in fair value of contingent earn-out consideration liability

452

417

768

323

Restructuring

7,936

Non-GAAP operating income

$

71,835

$

54,083

$

169,760

$

131,058

GAAP net income

$

47,956

$

33,468

$

106,964

$

82,150

Adjusted to exclude the following:

Acquisition and other related expenses

30

Stock-based compensation

11,771

13,984

35,573

34,843

Amortization of acquired intangibles

1,061

1,198

3,457

3,595

Change in fair value of contingent earn-out consideration liability

452

417

768

323

Restructuring

7,936

Income tax effect of non-GAAP adjustments (1)

(2,790

)

(3,276

)

(10,024

)

(8,146

)

Non-GAAP net income

$

58,450

$

45,791

$

144,674

$

112,795

Non-GAAP net income margin

43.2

%

39.7

%

40.5

%

36.6

%

Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:

Basic

186,309

192,805

191,302

192,963

Diluted

200,463

212,065

207,265

213,656

Non-GAAP net income per share attributable to Class A and Class B stockholders:

Basic

$

0.31

$

0.24

$

0.76

$

0.58

Diluted

$

0.29

$

0.22

$

0.70

$

0.53

(1) For the three and nine months ended December 31, 2023 and 2022, management used an estimated annual effective non-GAAP tax rate of 21.0%.

Investor Relations Contact:

Perry Gold

[email protected]

Media Contact:

Amanda Cox

[email protected]

Source: Doximity

Categories

Business Wire Press Releases

Next Articles